温肾消喘膏方防治支气管哮喘的疗效及对免疫指标的影响  

Preventive and Therapeutic Effect of Wenshen Xiaochuan Paste Recipe for Bronchial Asthma and Its Influence on Immune Indexes

作　　者：李影捷 惠萍 宋天云 陈照南 范发才 

机构地区：[1]江门市五邑中医院,广东江门529031

出　　处：《广州中医药大学学报》2015年第5期813-816,共4页Journal of Guangzhou University of Traditional Chinese Medicine

基　　金：广东省江门市科技计划项目(编号:江科[2013]83号)

摘　　要：【目的】观察温肾消喘膏方防治支气管哮喘的临床疗效并探讨其作用机制。【方法】将80例支气管哮喘患者随机分为治疗组和对照组各40例。对照组给予吸入表面激素等常规西医治疗,治疗组在对照组基础上给予服用温肾消喘膏方治疗,2组疗程均为60 d,并随访10个月。观察2组临床疗效及治疗前后外周血T淋巴细胞亚群CD3+、CD4+、CD8+、CD4+/CD8+比值和血清特异性总Ig E水平的变化情况。【结果】(1)治疗后及12个月后,2组哮喘控制测试量表(ACT)评分均较治疗前显著提高(P<0.05或P<0.01)。治疗后2组ACT评分比较,差异无统计学意义(P>0.05);但12个月后2组ACT评分比较,差异有统计学意义(P<0.05)。(2)治疗后,2组1年内哮喘急性发作次数均减少,与治疗前比较,差异均有统计学意义(P<0.05);且治疗组在减少哮喘急性发作次数方面优于对照组,差异有统计学意义(P<0.05)。(3)治疗组治疗后血清Ig E、CD4+水平、CD4+/CD8+比值均显著降低,CD8+水平显著升高,与治疗前比较,差异均有统计学意义(P<0.05);而对照组治疗前后各项免疫指标差异均无统计学意义(P>0.05);治疗组对各项免疫指标的改善作用均优于对照组,差异均有统计学意义(P<0.05)。【结论】温肾消喘膏方防治哮喘具有良好的临床疗效,其作用机制可能是通过调节T淋巴细胞亚群和降低血清Ig E水平,从而抑制气道炎症,改善哮喘患者的免疫功能。Objective To observe the clinical efficacy of Wenshen Xiaochuan Paste Recipe （WXPR） in preventing bronchial asthma, and to explore the mechanism. Methods Eighty patients were randomly divided into treatment group and control group. Each group had 40 patients. The control group was treated by conventional western medicine such as inhalation of steroid, and the treatment group was given oral use of WXPR based on the treatment for the control group. Treatment for both groups covered 60 days, and the follow-up lasted 10 months. The clinical outcomes included the clinical efficacy and immune indexes of peripheral blood T lymphocyte subsets CD3＋, CD4＋, CD8＋and CD4＋/CD8＋ratio, and the serum IgE level. Results （1） After treatment and 12 months later, the scores of asthma control test （ACT ） in the two groups were increased obviously as compared with those before treatment, and there were statistically significant differences （P〈0.05 or P〈0.01） . The differences of ACT scores between the two groups were insignificant after treatment （ P〉0.05） , but were significant （ P〈0.05） 12 months later. （2） Within one year after treatment, the frequency of acute asthma attack was decreased in both groups （P〈0.05 compared with that before treatment）, and the treatment group had better effect on decreasing the attack frequency than the control group （P〈0.05）. （3） After treatment, the serum IgE, CD4＋level, and CD4＋/CD8＋ ratio were decreased significantly, while CD8＋ level was increased in the treatment group, and there were statistically significant differences （ P〈0.05 compared with those before treatment）. However, the differences of immune indexes in the control group were insignificant before and after treatment （ P〉0.05）. The improvement of immune indexes in the treatment group was superior to that in the control group （ P〈0.05）. Conclusion WXPR has good clinical efficacy in preventing and treating bronchial asthma. The mechanism is related with

关 键 词：支气管哮喘/中西医结合疗法 温肾消喘膏方/治疗应用 免疫指标 

分 类 号：R259.622[医药卫生—中西医结合]